AbbVie
More News
-
AbbVie cancer drug fails two late-stage trials
Abbvie's shares were marginally down after the bell on Wednesday
FOLLOW US
This material may not be published, broadcast, rewritten, redistributed or derived from. Unless otherwise stated, all content is copyrighted © 2024 The Express Tribune.
